Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of human therapeutic proteins designed to increase the survivability of premature-born infants. The company's human therapeutic proteins are made using advanced plant-based genetic engineering and synthetic biology techniques and it also offers a plant based expression technology which comprises optimal combinations of novel synthetic promoters, combined with enhancer and purification components, enabling medical professionals to offers drugs with superior clinical efficacy at low cost that can significantly improve the health status of citizens.
You’re viewing a free company profile from the PitchBook Platform. To explore AzarGen Biotechnologies’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Angel (individual) | 07-Jan-2016 | $3.1M | 00.00 | Completed | Startup | |
1. Seed Round | Completed | Startup |